an antidiabetic drug for treatment of Type 2 diabetes. It is an individual from the new SGLT2 class of antidiabetic solution that additionally incorporates empagloflozin (Jardiance) and dapagliflozin (Farxiga). Canagliflozin is additionally sold in mix with metformin under the brand name “Invokamet”.
invokana and Invokamet are made and advertised in the U.S. by Janssen pharmaceuticals which is a backup of Johnson and Johnson, one of the biggest pharmaceutical organizations on the planet with income of over $74 billion every year.
invokana was affirmed in 2013 as the first SGLT2 (sort 2 sodium-glucose co-transporter) inhibitor. As it works uniquely in contrast to other hostile to diabetes pharmaceuticals available, it was wanted to be helpful for patients who did not react well to other drug. Sadly, numerous drugs for Type 2 diabetes have created genuine medicinal harm. The SGLT2 class rooftop solutions has been embroiled in a higher-than-ordinary advancement of diabetic ketoacidosis, an existence undermining condition.
invokana works by setting off the kidneys to discharge overabundance blood glucose through the urine. It is demonstrated for treatment of patients with Type 2 diabetes, which can’t be controlled through eating regimen and activity. It is not to be endorsed to those with Type 1 diabetes or for treatment of diabetic ketoacidosis.
Diabetic ketoacidosis happens when the body does not have enough insulin to oversee glucose levels. The body starts smoldering unsaturated fats, which brings about a waste item called acidic ketone bodies. These ketones are what trigger the indications of ketoacidosis. Those side effects incorporate spewing, parchedness, disarray, weakness, and stomach torment. In uncommon cases, untreated ketoacidosis can bring about trance state and even passing. While no passings have been accounted for with the utilization of invokana or Invokamet, the risk exists.
A conceivably deadly reaction of Invokana may prompt claims against a modest bunch of medication producers. The pharmaceutical treats Type 2 diabetes yet triggers hazardous levels of blood acids, which drove the FDA to sound an alert about the medications.
The U.S. Food and Drug Administration (FDA) has strengthened the warning for the type 2 diabetes medicine canagliflozin (Invokana, Invokamet) related to the increased risk of bone fractures and added new information about decreased bone mineral density. Bone mineral density relates to the strength of a person’s bones. To address these safety concerns, we added a new Warning and Precaution and revised the Adverse Reactions section of the Invokana and Invokamet drug labels.
Health care professionals should consider factors that contribute to fracture risk prior to starting patients on canagliflozin. Patients should talk to their health care professionals about factors that may increase their risk for bone fracture. Patients should not stop or change their diabetes medicines without first talking to their health care professional.
Canagliflozin is a prescription medicine used with diet and exercise to lower blood sugar in adults with type 2 diabetes. It belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors. Untreated, type 2 diabetes can lead to serious problems, including blindness, nerve and kidney damage, and heart disease. Canagliflozin lowers blood sugar by causing the kidneys to remove sugar from the body through the urine. It is available as a single-ingredient product under the brand name Invokana and also in combination with the diabetes medicine metformin under the brand name Invokamet.
Information about the risk of bone fractures was already in the Adverse Reactions section of the drug label at the time of canagliflozin’s approval. Based on updated information about bone fractures from several clinical trials, we revised the drug label and added a new Warning and Precaution. The additional data confirm the finding that fractures occur more frequently with canagliflozin than placebo, which is an inactive treatment. Fractures can occur as early as 12 weeks after starting the drug. In the clinical trials, when trauma occurred prior to a fracture, it was usually minor, such as falling from no more than standing height. In addition, we have added new information about the risk of decreased bone mineral density to the canagliflozin label. A clinical trial that we required the manufacturer of canagliflozinto conduct evaluated changes to bone mineral density over two years in 714 elderly individuals and showed that canagliflozin caused greater loss of bone mineral density at the hip and lower spine than a placebo. This new safety information has been added to the Adverse Reactions section of the drug label.
We are continuing to evaluate the risk of bone fractures with other drugs in the SGLT2 inhibitor class, including dapagliflozin (Farxiga, Xigduo XR) and empagliflozin (Jardiance, Glyxambi, Synjardy), to determine if additional label changes or studies are needed. We urge health care professionals and patients to report side effects involving canagliflozin or other SGLT2 inhibitors to the FDA MedWatch program.